Skip to main content

Building

A better future

through education, skill development and research

LEARN MORE

Analysis Examines Link between Bone Turnover Markers and Fracture Risk in Osteoporosis Trials

Pooled data from 14 osteoporosis clinical trials of anti-resorptive drugs indicate that patients who have reduced levels of two bone turnover markers during treatment have lower risks of later experiencing vertebral fractures. No bone turnover markers were significantly associated with non-vertebral or hip fracture risks, according to the Journal of Bone and Mineral Research analysis.

Wednesday, January 10, 2018 12:01 am EST
"Osteoporosis drug development would greatly benefit from biomarkers that predict drug efficacy, and these results suggest some serum bone turnover markers may be useful for such a purpose"

Pooled data from 14 osteoporosis clinical trials of anti-resorptive drugs indicate that patients who have reduced levels of two bone turnover markers during treatment have lower risks of later experiencing vertebral fractures. No bone turnover markers were significantly associated with non-vertebral or hip fracture risks, according to the Journal of Bone and Mineral Research analysis.

The findings may be helpful in the development of anti-resorptive drugs for osteoporosis, particularly in choosing the dose and treatment schedule.

“Osteoporosis drug development would greatly benefit from biomarkers that predict drug efficacy, and these results suggest some serum bone turnover markers may be useful for such a purpose,” said lead author Dr. Douglas Bauer, of the University of California, San Francisco.

Additional Information

Link to Study: http://onlinelibrary.wiley.com/doi/10.1002/jbmr.3355/full

About Journal

The JBMR publishes highly competitive original manuscripts, reviews, and special articles in basic and clinical science relevant to bone, muscle and mineral metabolism. Manuscripts are published on the biology and physiology of bone and muscle, relevant systems biology topics (e.g. osteoimmunology), and the pathophysiology and treatment of sarcopenia and disorders of bone and mineral metabolism.

Multimedia Files:

Preview image

Contact:

Penny Smith
+44 (0) 1243 770448
sciencenewsroom@wiley.com

Business Wire NewsHQsm